New TIL Therapy Trial Options: PD1 Knockout TIL Therapy

6 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
In this informative presentation from the UPMC Patient Symposium on Melanoma, Darcy Ploucha, PA-C, MPAS, a physician assistant and melanoma expert from UPMC Hillman Cancer Center, explores emerging clinical trial options in Tumor-Infiltrating Lymphocyte (TIL) therapy—specifically focusing on PD1 knockout TIL therapy.

Learn how this cutting-edge immunotherapy approach aims to enhance the body's ability to fight melanoma by modifying immune cells to overcome resistance and improve treatment outcomes. Darcy provides a clear overview of how PD1 knockout technology works, the goals of current clinical trials, and what patients need to know about eligibility and participation.

???? Topics Covered:

Basics of TIL therapy

What is PD1 and why knocking it out matters

Current clinical trial landscape

Potential benefits and risks

How to talk to your care team about trial options

???? Presented by: Darcy Ploucha, PA-C, MPAS
???? UPMC Hillman Cancer Center
???? Recorded at the UPMC Melanoma Patient Symposium

???? Don’t forget to like, share, and subscribe for more updates on melanoma care and research.

#Melanoma #CancerResearch #TILTherapy #Immunotherapy #UPMC #PD1Knockout #ClinicalTrials #MelanomaAwareness
Category
Oncology
Be the first to comment

Up Next